<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":5658,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 U.S.P.Q.2d 1445 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/55858d43ba3198188cf428e920907029'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/55858d43ba3198188cf428e920907029'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1HEKHU003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HEKHU003">Previous Result: <span>Nicewander v. MTC Financial, Inc., Civil...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1HEKI0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HEKI0003">Next Result: <span>Blue Dolphin Charters, Ltd. v. Knight &amp; ...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 U.S.P.Q.2d 1445 (Fed. Cir. 2012), Court Opinion'>
Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 U.S.P.Q.2d 1445 (Fed. Cir. 2012),...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 U.S.P.Q.2d 1445 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HEJSK003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Aventis Pharma S.A. v. Hospira, Inc.</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1445</div>
<div class='displayCitation'>2012 BL 84628</div>
<div class='displayCitation'>675 F.3d 1324</div>
<div class='displayCitation'>bna a0d1k0p7p5</div>
<div class='displayCitation'>bna a0d1p4u5u5</div>
<div class='displayCitation'>wkffecase:25929674</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HEJSK003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 U.S.P.Q.2d 1445 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Aventis Pharma S.A. v. Hospira, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/55858d43ba3198188cf428e920907029/document/X1HEJSK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HEJSK003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HEJSK003" /><input id="title" name="title" type="hidden" value="Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 102 U.S.P.Q.2d 1445 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="55858d43ba3198188cf428e920907029" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HEJSK003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%35%35%38%35%38d%34%33ba%33%31%39%38%31%38%38cf%34%32%38e%39%32%30%39%30%37%30%32%39%2Fdocument%2FX%31HEJSK%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/55858d43ba3198188cf428e920907029/bcite/X1HEJSK003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/55858d43ba3198188cf428e920907029/bcite/X1HEJSK003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/55858d43ba3198188cf428e920907029/bcite/X1HEJSK003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/55858d43ba3198188cf428e920907029/related_content/X1HEJSK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1699327115267";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">675 F.3d 1324</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1445</div>
<div class="cite" data-cite-type="DocketNumber">2011-1018</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 84628</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
AVENTIS PHARMA S.A. and Sanofi-Aventis U.S., LLC,
Plaintiffs-Appellants, v. HOSPIRA, INC., Defendant-Appellee, and Apotex
Inc. and Apotex Corp., Defendants-Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2011-1018.
</center></p>
<p><center>
April 9, 2012.
<span CLASS="page_no" data-cite="102 uspq 2d 1446" data-cite-type="ReporterOfDecisions" data-cite-pageno="1446" data-primary-citation="102 U.S.P.Q.2d 1445">[**1446]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_913488" href="#headnote_ref_pq2-dec_913488">[1]</a> <span>Patent construction &mdash; Claims &mdash; Broad or narrow </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1303" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1303">&#9658;125.1303</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patent construction &mdash; Claims &mdash; Defining terms </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1305" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1305">&#9658;125.1305</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court properly construed term &ldquo;perfusion,&rdquo;
in claim directed to taxane derivative compounds, as &ldquo;an injectable solution containing the active pharmaceutical ingredient and an aqueous infusion fluid,&rdquo; and term does not include efficacy, safety, and stability limitations, since neither claim, specification, nor prosecution history suggest that claimed perfusion must satisfy certain safety or efficacy standards, since patentee did not clearly set forth definition of claim term other than its plain and ordinary meaning, or disavow full scope of term either in specification or during prosecution, and since &ldquo;perfusion&rdquo; thus will not be narrowed beyond its plain and ordinary meaning to include stability limitation.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_913489" href="#headnote_ref_pq2-dec_913489">[2]</a> <span>Patent construction &mdash; Claims &mdash; Broad or narrow </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1303" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1303">&#9658;125.1303</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patent construction &mdash; Claims &mdash; Defining terms </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1305" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1305">&#9658;125.1305</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Term &ldquo;perfusion,&rdquo; in claim directed to taxane derivative compounds, is properly construed to mean &ldquo;an injectable solution containing the active pharmaceutical ingredient and an aqueous infusion fluid,&rdquo; and does not include stability limitations, since, by expressly stating that &ldquo;perfusion&rdquo; is not associated with &ldquo;anaphylactic or alcohol intoxication manifestations,&rdquo; plain language of claim indicates that the term has its ordinary meaning subject only to those specifically enumerated limitations, since specification refers to perfusions with stability of at least eight hours, and discloses examples of perfusions having stabilities exceeding eight hours, but specification expressly instructs that disclosed examples &ldquo;are not to be considered as limiting the invention,&rdquo; since prosecution history does not evidence clear and convincing disavowal of claim scope, and since extrinsic evidence can be considered in determining ordinary meaning of claim term to person of ordinary skill in art, and testimony of both parties' experts in present case was consistent with intrinsic evidence and supports conclusion that ordinary meaning of &ldquo;perfusion&rdquo;
does not include stability limitation.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_913490" href="#headnote_ref_pq2-dec_913490">[3]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; References and claims as whole </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0904" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0904">&#9658;115.0904</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court&rsquo;s judgment that claimed &ldquo;perfusion&rdquo;
in patent directed to taxane derivative compounds is invalid under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/1?citation=35%20USC%20103&amp;summary=yes&amp;showHeadnotes=yes#jcite">35 U.S.C. &sect;103</a> is affirmed, since district court properly construed term &ldquo;perfusion&rdquo;
to mean &ldquo;an injectable solution containing the active pharmaceutical ingredient and an aqueous infusion fluid,&rdquo; and since it is undisputed that, under district court's claim construction, claim was obvious in view of prior art.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_913491" href="#headnote_ref_pq2-dec_913491">[4]</a> <span>Patentability/Validity &mdash; Construction of claims </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.03">&#9658;115.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; References and claims as whole </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0904" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0904">&#9658;115.0904</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court hearing action for infringement of patent directed to taxane derivative compounds properly found that claimed &ldquo;composition,&rdquo;
which can be either stock solution or perfusion, is invalid under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/1?citation=35%20USC%20103&amp;summary=yes&amp;showHeadnotes=yes#jcite">35 U.S.C. &sect;103</a>, since district court's unchallenged finding that claimed stock solutions were obvious in light of prior art also renders &ldquo;composition&rdquo; in claim obvious, regardless of whether district court correctly construed phrase claim term &ldquo;essentially free or free of ethanol&rdquo;
as it relates to perfusions.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_913492" href="#headnote_ref_pq2-dec_913492">[5]</a> <span>Infringement &mdash; Defenses &mdash; Fraud or unclean hands </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1111" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1111">&#9658;120.1111</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Pleadings </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.26" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.26">&#9658;410.26</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court did not abuse its discretion by allowing patent infringement defendant to amend counterclaim for inequitable conduct in order to identify withheld references, or by allowing second defendant to amend pleadings to add counterclaim for inequitable conduct, even though amendments were allowed shortly after scheduling deadline, since court found that timing of first motion to amend did not appear to have been product of bad faith, and that plaintiff would not be unduly prejudiced, and since there was good cause for amendments under circumstances of case, including temporal proximity of amendments to inventor&rsquo;s deposition.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_913493" href="#headnote_ref_pq2-dec_913493">[6]</a> <span>Practice and procedure in Patent and Trademark Office &mdash; Prosecution &mdash; Duty of candor &mdash; Materiality </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=110.0903.04" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="110.0903.04">&#9658;110.0903.04</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Defenses &mdash; Fraud or unclean hands </span> <a href="http://www.bloomberglaw.com/document/1699327115267/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1111" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1111">&#9658;120.1111</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court's finding that inventor withheld references with specific intent to deceive U.S. Patent and Trademark Office was not clearly erroneous, since district court found that withheld references were &ldquo;but-for&rdquo; material to patentability, and court made distinct intent and materiality findings rather than employing now-abrogated &ldquo;sliding scale&rdquo; approach, since invalidity findings based on withheld prior art references have been affirmed, and thus references were necessarily &ldquo;material,&rdquo; and since district court rejected inventor's explanations for withholding references, based on record evidence and determination that explanation was not credible, and concluded that &ldquo;[t]here simply is no justification for telling the [PTO] about the prior art disclosing the problem [the inventor]
examined while concealing key prior art disclosing the solution he chose.&rdquo;</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of Delaware, Gregory M. Sleet, Chief Judge.
</p></div>
<span CLASS="page_no" data-cite="675 f 3d 1325" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1325" data-primary-citation="675 F.3d 1324">[*1325]</span> <div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="675 f 3d 1326" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1326" data-primary-citation="675 F.3d 1324">[*1326]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="675 f 3d 1327" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1327" data-primary-citation="675 F.3d 1324">[*1327]</span> 
</p></div>
</div>
<div id="para2" printdualcolumn="true"><p>
  George F. Pappas, Covington &amp; Burling, LLP, of
Washington, DC, argued for plaintiffs-appellants Aventis Pharma
S.A., et al. With him on the brief were Christopher N. Sipes,
Kevin B. Collins, Michael N. Kennedy, and Roger A. Ford.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  James F. Hurst, Winston &amp; Strawn, LLP, of Chicago, IL,
argued for defendant-appellee, Hospira, Inc. With him on the
brief was Imron T. Aly. Of counsel on the brief were Steffen N.
Johnson, Geoffrey P. Eaton, and Jacob R. Loshin, of Washington,
DC. Of counsel was Andrew Nichols.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Richard T. Ruzich, Duane Morris LLP, of Washington, DC, argued
for defendants-appellees, Apotex Inc., et al. With him on the
brief were Arthur M. Dresner, Kerry B. Mctigue, Kristina
Caggiano and Matthew C. Mousley. Of counsel on the brief was
Shashank Upadhye, Apotex, Inc., of Toronto, Ontario, Canada.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before LINN, DYK, and PROST, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  PROST, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Aventis Pharma S.A. and Sanofi-Aventis U.S., L.L.C.
(collectively "Sanofi") filed suit against Hospira, Inc.
("Hospira") and Apotex Inc. and Apotex Corp. (collectively
"Apotex") under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e) for infringement of <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">U.S.
Patent Nos. 5,750,561</a> ("&prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a>") <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">and 5,714,512</a> (&prime;"<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512
patent</a>"). After a bench trial, the district
<span CLASS="page_no" data-cite="675 f 3d 1328" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1328" data-primary-citation="675 F.3d 1324">[*1328]</span> 
court found, inter alia, that claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a>
and claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> were invalid for obviousness
under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>, that claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> was
not infringed, and that both the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a> were
unenforceable for inequitable conduct. Sanofi has appealed. For
the reasons set forth below, we affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              I. BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a> are pharmaceutical patents related to
the administration of the chemotherapy cancer drug docetaxel,
which is marketed under the brand-name Taxotere. The patents
are assigned to Aventis Pharma S.A., and Sanofi-Aventis U.S.,
L.L.C. is the holder <span CLASS="page_no" data-cite="102 uspq 2d 1447" data-cite-type="ReporterOfDecisions" data-cite-pageno="1447" data-primary-citation="102 U.S.P.Q.2d 1445">[**1447]</span> of the New Drug Application for Taxotere.
Docetaxel is a successor to the cancer drug paclitaxel,
marketed as Taxol, and the composition for docetaxel was
covered by now-expired <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2204843G0J?jcsearch=usp%204814470&amp;summary=yes#jcite">U.S. Patent No. 4,814,470</a> (&prime;"<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2204843G0J?jcsearch=usp%204814470&amp;summary=yes#jcite">470
patent</a>"). Both docetaxel and paclitaxel belong to the class of
compounds known as taxanes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Taxanes are administered through an intravenous infusion,
accomplished by slowly delivering the drug in a diluted aqueous
solution called a "perfusion." Taxanes, however, have low
solubility in water and tend to precipitate, i.e., form solid
clumps, and come out of solution. To delay precipitation,
taxanes are mixed with additives like surfactants and ethanol;
these additives stabilize the perfusion and delay the amount of
time before precipitation <span CLASS="page_no" data-cite="2012 bl 84628 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> occurs. The taxane is combined with
the additives to form a "stock solution" which is then mixed
into an injectable aqueous solution, such as saline, to form a
perfusion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the prior art, the surfactant Cremophor was used with
taxanes to form the stock solution, but it was known to trigger
serious allergic reactions, including anaphylactic shock. &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561
patent</a> col.1 ll.59-63; &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> col.2 ll.31-35. The &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and
&prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a> relate to using surfactants other than Cremophor
with docetaxel and decreasing the amount of ethanol to reduce
alcohol intoxication and anaphylactic effects in patients.
After Hospira and Apotex applied for Federal Drug
Administration ("FDA") approval to market generic versions of
Taxotere, Sanofi filed suit against them for infringement of
the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a>. Only claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> and
claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> are at issue on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> is titled "Compositions containing taxane
derivatives" and describes taxane compositions, including a
perfusion that avoids anaphylactic and alcohol intoxication
manifestations. Claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> recites:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  5. A perfusion, which contains approximately 1 mg/ml
  or less of compound of formula as defined in claim 1,
  and which contains less than 35 ml/1 of ethanol and
  less than 35 ml/1 of polysorbate, wherein said
  perfusion is capable of being injected without
  anaphylactic or alcohol intoxication manifestations
  being associated therewith.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> is titled "New compositions containing taxane
derivatives," and discloses taxane compositions with reduced
ethanol. Claim 7 depends from claims 1 and 6. As corrected by a
Certificate of Correction, those claims recite:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. A composition comprising a compound of the formula
<span CLASS="page_no" data-cite="675 f 3d 1329" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1329" data-primary-citation="675 F.3d 1324">[*1329]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1HEJSK003?documentName=69212_c">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  in which Ar is unsubstituted phenyl, R<sub>7</sub> is
  phenyl or tert butoxy, R<sub>6</sub> is hydrogen,
  R<sub>5</sub> is acetyloxy or hydroxy, R<sub>3</sub>
  and R<sub>4</sub> taken together form an oxo radical,
  R<sub>1</sub> is hydroxy and R<sub>2</sub> is
  hydrogen, said composition being dissolved in a
  surfactant selected from polysorbate, polyoxyethylated
  vegetable oil, and polyethoxylated castor oil, said
  composition being essentially free or free of ethanol.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  6. The composition of claim 1, wherein R<sub>5</sub>
  is hydroxy and R<sub>7</sub> is tert butoxy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  7. The composition of claim 6, wherein said surfactant
  is polysorbate.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After a bench trial, the court found that claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512
patent</a> was invalid as obvious and not infringed by Hospira or
Apotex. With respect to claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a>, the court
found that Hospira and Apotex did infringe but concluded that
the claim was obvious. The court also determined that the &prime;<cite>512</cite>
and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> patents were unenforceable for inequitable conduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                             II. DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Sanofi challenges the district court's construction
of two claim terms: "perfusion" in claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a>
and "essentially free or free of ethanol" in claim 7 of the
&prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a>. Based on the district court's constructions,
Sanofi argues that the court erred in finding that both claims
were invalid for obviousness under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a> and that
Apotex's and Hospira's accused products did not infringe claim
7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a>. <span CLASS="page_no" data-cite="2012 bl 84628 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> Additionally, Sanofi contends that the
court erred in finding that the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a> were
unenforceable for inequitable conduct. We have jurisdiction
under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                      A. Claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 Patent</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Claim construction is a question of law reviewed de novo.
<i>Cybor Corp. v. FAS Techs.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">138 F.3d 1448</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">1454-55</a>
(Fed. Cir. 1998) (en banc). <span CLASS="page_no" data-cite="102 uspq 2d 1448" data-cite-type="ReporterOfDecisions" data-cite-pageno="1448" data-primary-citation="102 U.S.P.Q.2d 1445">[**1448]</span> Claim terms generally are construed
in accordance with the ordinary and customary meaning they
would have to one of ordinary skill in the art in light of the
specification and the prosecution history. <i>Phillips v. AWH</i>
<i>Corp.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d 1303</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">1312</a> (Fed. Cir. 2005) (en banc).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Before the district court, the parties initially agreed to
construe "perfusion" in claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> as "a
solution suitable for infusion into patients including at least
active pharmaceutical ingredient and an aqueous infusion fluid
such as physiological saline or glucose." <i>Aventis Pharma</i>
<i>S.A. v. Hospira, Inc.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20f%20supp%202d%20305&amp;summary=yes#jcite">743 F.Supp.2d 305</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20f%20supp%202d%20305&amp;summary=yes#jcite">332</a>
(D.Del. 2010). The parties, however, later realized that they
did not agree on the meaning of the phrase "suitable for
infusion into patients" in their proposed construction, leading
Sanofi to ask the district court to require that the claimed
"perfusion" also be effective for treatment, safe, and stable
(i.e., not precipitate) for at least eight hours. The court
declined to impose these additional limitations and instead
<span CLASS="page_no" data-cite="675 f 3d 1330" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1330" data-primary-citation="675 F.3d 1324">[*1330]</span> 
construed "perfusion" to mean "an injectable solution
containing the active pharmaceutical ingredient and an aqueous
infusion fluid." <i>Id.</i> at 333. On appeal, Sanofi argues
that the district court erred in not construing "perfusion" to
include these additional efficacy, safety, and stability
limitations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_913488" href="#headnote_pq2-dec_913488">[1]</a> We can easily dispose of Sanofi's first two limitations.
Neither the claims, the specification, nor the prosecution
history suggest that the claimed perfusion must satisfy certain
safety or efficacy standards. We previously have refused to
impose such limitations when not required by the language of
the claims or the specification, <i>see Mitsubishi Chem. Corp.</i>
<i>v. Barr Labs., Inc.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FVEB2003?jcsearch=435%20f%20appx%20927&amp;summary=yes#jcite">435 Fed.Appx. 927</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FVEB2003?jcsearch=435%20f%20appx%20927&amp;summary=yes#jcite">934-35</a> (Fed. Cir.
2011); <i>I ovate Health Scis., Inc. v. Bio-Engineered</i>
<i>Supplements &amp; Nutrition, Inc.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1C5BLQ003?jcsearch=586%20f%203d%201376&amp;summary=yes#jcite">586 F.3d 1376</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1C5BLQ003?jcsearch=586%20f%203d%201376&amp;summary=yes#jcite">1382</a>
(Fed. Cir. 2009), and decline to do so here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Regarding Sanofi's eight-hour stability limitation, Sanofi does
not contend that "perfusion," as that term is normally
understood in the art, includes such a limitation. Instead,
Sanofi argues that based on how the term is used in the context
of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a>, the claimed "perfusion" must demonstrate at
least eight hours of stability. <i>See</i> Oral Argument
3:05-3:10, <i>available at</i>
http://www.cafc.uscourts.gov/oral-argument-recordings/2011-1018
/all. This court recently reiterated the stringent standard for
narrowing a claim term beyond its plain and ordinary meaning in
<i>Thorner v. Sony Computer Entertainment America L.L.C.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">669 F.3d 1362</a> (Fed. Cir. 2012). There, we explained that we will
only interpret a claim term more narrowly than its ordinary
meaning under two circumstances: "1) when a patentee sets out a
definition and acts as [its] own lexicographer, or 2) when the
patentee disavows the full scope of a claim term either in the
specification or during prosecution." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">Id. at 1365</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "To act as its own lexicographer, <span CLASS="page_no" data-cite="2012 bl 84628 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> a patentee must `clearly set
forth a definition of the disputed claim term' other than its
plain and ordinary meaning." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">Id</a>.</i> (quoting <i>CCS</i>
<i>Fitness, Inc. v. Brunswick Corp.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X4IU5C?jcsearch=288%20f%203d%201359&amp;summary=yes#jcite">288 F.3d 1359</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X4IU5C?jcsearch=288%20f%203d%201359&amp;summary=yes#jcite">1366</a>
(Fed. Cir. 2002)). In other words, "the patentee must `clearly
express an intent' to redefine the term." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">Id</a>.</i> This
clear expression need not be in <i>haec verba</i> but may be
inferred from clear limiting descriptions of the invention in
the specification or prosecution history. Similarly, to disavow
claim scope, "[t]he patentee may demonstrate intent to deviate
from the ordinary and accustomed meaning of a claim term by
including in the specification expressions of manifest
exclusion or restriction, representing a clear disavowal of
claim scope." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">Id. at 1366</a> (quoting <i>Teleflex, Inc.</i>
<i>v. Ficosa N. Am. Corp.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">299 F.3d 1313</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XFL2AO?jcsearch=299%20f%203d%201313&amp;summary=yes#jcite">1325</a>
(Fed. Cir. 2002)). Moreover, "[i]t is . . . not enough that the
only embodiments, or all of the embodiments, contain a
particular limitation" to limit a claim term beyond its
ordinary meaning. <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">Id</a>.</i> Here, because neither exception
applies, the district court correctly did not include an
eight-hour stability limitation in its construction of
"perfusion."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_913489" href="#headnote_pq2-dec_913489">[2]</a> We begin our analysis with the language of the claims.
<i>Phillips</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d at 1312</a>. Claim 5 requires that the
"perfusion" be "capable of being injected without anaphylactic
or alcohol intoxication manifestations," but contains no
limitations with respect to the claimed perfusion's stability.
Had the patentee similarly intended to require that the
"perfusion" display a certain duration of stability, it could
have included such a limitation in the claim but notably did
not. By expressly identifying the specific characteristics of
the "perfusion," i.e., that it is not associated with
"anaphylactic or alcohol intoxication manifestations," the
plain language of claim 5 indicates that the term has its
ordinary
<span CLASS="page_no" data-cite="675 f 3d 1331" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1331" data-primary-citation="675 F.3d 1324">[*1331]</span> 
meaning subject only to those specifically enumerated
limitations.
<span CLASS="page_no" data-cite="102 uspq 2d 1449" data-cite-type="ReporterOfDecisions" data-cite-pageno="1449" data-primary-citation="102 U.S.P.Q.2d 1445">[**1449]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This interpretation of "perfusion" also is consistent with the
teachings of the specification. Although the specification does
refer to perfusions with a stability of at least eight hours,
<i>see</i> &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> col.2 ll.43-45 ("The new perfusions
[referring to examples in the specification] are stable from a
physical standpoint, that is to say no precipitation phenomenon
is seen to appear within approximately 8 hours."), and the
disclosed examples of perfusions have stabilities exceeding
eight hours, <i>see <cite>id</cite>.</i> at col.2 1.59-col.3 1.26, these
general descriptions of the characteristics of embodiments do
not suffice to limit the claims. <i>See Thorner</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H2Q26003?jcsearch=101%20U.S.P.Q.2d%201457&amp;summary=yes#jcite">669 F.3d at 1366</a> ("It is likewise not enough that the only embodiments,
or all of the embodiments, contain a particular limitation.").
Indeed, the specification expressly instructs that the
disclosed examples "are not to be considered as limiting the
invention."&prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> col.2 ll.53-54. Moreover, in contrast to
the specification's discussion of anaphylactic and alcohol
intoxication manifestations, nothing in the specification
indicates that a minimum stability of eight hours is an
essential feature of the claimed perfusion or an advantage of
the perfusion over the prior <span CLASS="page_no" data-cite="2012 bl 84628 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> art. <i>See Liebel-Flarsheim Co.</i>
<i>v. Medrad, Inc.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XE42MU?jcsearch=358%20f%203d%20898&amp;summary=yes#jcite">358 F.3d 898</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XE42MU?jcsearch=358%20f%203d%20898&amp;summary=yes#jcite">906-09</a> (Fed. Cir. 2004)
(distinguishing cases where the court narrowly construed an
otherwise broad claim term).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nor does the prosecution history evidence a clear and
unmistakable disavowal of claim scope. The prosecution history
can offer insight into the meaning of a particular claim term,
but the "[c]laim language and the specification generally carry
greater weight." <i>HTC Corp. v. IP-Com GmbH &amp; Co.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H27G0003?jcsearch=667%20f%203d%201270&amp;summary=yes#jcite">667 F.3d 1270</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1H27G0003?jcsearch=667%20f%203d%201270&amp;summary=yes#jcite">1276</a> (Fed. Cir. 2012). Here, the patentee's
observation during prosecution that the perfusions in the Tarr
reference demonstrated signs of precipitation after four hours
and thirty minutes neither indicates that the claimed perfusion
has a special definition nor clearly and unmistakably manifests
the patentee's intention to limit claim 5 to perfusions that
are stable for at least eight hours. The Tarr reference was not
directed to the two-solvent solution of claim 5 but to a prior
art three-solvent solution; the argument was that the presence
of the third solvent materially affected the characteristics of
the claimed composition.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Lastly, we reject Sanofi's argument that the district court
improperly relied on extrinsic evidence in the form of expert
testimony in construing this claim term. According to Sanofi,
because the intrinsic evidence alone dictates the proper
construction of perfusion, any extrinsic evidence is
irrelevant. A district court, however, has the discretion to
take expert testimony into account in determining the ordinary
meaning of a claim term to one skilled in the
art. <i>Phillips</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d at 1319</a> ("[B]ecause extrinsic
evidence can help educate the court regarding the field of the
invention and can help the court determine what a person of
ordinary skill in the art would understand claim terms to mean,
it is permissible for the district court in its sound
discretion to admit and use such evidence."). Here, the
district court heard testimony from both sides' experts,
including testimony from Sanofi's expert, Dr. Howard Burris,
which was consistent with the intrinsic evidence and supports
the conclusion that the ordinary meaning of a perfusion does
not include the stability limitation proposed by Sanofi.
Consequently, the district court did not err in relying on
extrinsic evidence in construing this claim term.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In sum, we conclude that the patentee did not narrow the
ordinary meaning of "perfusion" in claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a>
by either acting as its own lexicographer or disclaiming claim
scope and therefore
<span CLASS="page_no" data-cite="675 f 3d 1332" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1332" data-primary-citation="675 F.3d 1324">[*1332]</span> 
agree with the district court that a "perfusion" is simply
"an injectable solution containing the active pharmaceutical
ingredient and an aqueous infusion fluid."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Having affirmed the court's claim construction, we next address
the district court's conclusion that claim 5 was invalid as
obvious under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>. A patent is invalid for
obviousness "if the differences between the subject matter
sought to be patented and the prior art are such that the
subject matter as a whole would have been obvious at the time
the invention was made to a person having ordinary skill in the
art to which <span CLASS="page_no" data-cite="2012 bl 84628 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> said subject matter pertains."
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a). "Obviousness is a question of law based on underlying
findings of fact." <i>In re Kubin</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">561 F.3d 1351</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1ASIN4003?jcsearch=561%20f%203d%201351&amp;summary=yes#jcite">1355</a>
(Fed. Cir. 2009). These underlying factual inquiries are (1) the
scope and content of the prior art; (2) the differences between
the prior art and the claims at issue; (3) the level of
ordinary skill in the art; and (4) any relevant secondary
considerations, such as commercial success, long felt but
unsolved needs, and the failure of others. <i>KSR Int'l Co. v.</i>
<i>Teleflex Inc.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">406</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007) (citing <i>Graham v. John Deere Co.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17-18</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966)). On
appeal from a bench trial, we review the district court's legal
<span CLASS="page_no" data-cite="102 uspq 2d 1450" data-cite-type="ReporterOfDecisions" data-cite-pageno="1450" data-primary-citation="102 U.S.P.Q.2d 1445">[**1450]</span> determination that an invention is obvious de novo and the
court's underlying factual determinations for clear error.
<i>Eli Lilly &amp; Co. v. Teva Pharms. USA, Inc.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">619 F.3d 1329</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E54SG003?jcsearch=619%20f%203d%201329&amp;summary=yes#jcite">1336</a> (Fed. Cir. 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_913490" href="#headnote_pq2-dec_913490">[3]</a> The district court found that claim 5 was obvious in light of
the prior art, including the Gueritte-Voegelein reference ("GV
reference") and the <i>Dictionnaire Vidal ("Vidal</i>
reference"). During oral argument, Sanofi's counsel confirmed
that under the district court's construction of "perfusion,"
Sanofi did not dispute that claim 5 was obvious based on the
prior art. Oral Argument 22:23-22:45. Because we have affirmed
the district court's construction of "perfusion," we also
affirm the district court's judgment that claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561
patent</a> is invalid under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                      B. Claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Sanofi argues that the district court erred in construing the
claim term "essentially free or free of ethanol" in claim 7 of
the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> as meaning that the claimed perfusion contains
"the same amount of ethanol as a stock solution with no more
than 5% ethanol by volume." <i>Aventis</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">743 F.Supp.2d at 359</a>. We need not resolve this issue, however, because its
resolution does not require reversal of the district court's
obviousness determination.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_913491" href="#headnote_pq2-dec_913491">[4]</a> Claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> claims a "composition," which the
parties agree can be either a stock solution or a perfusion.
With respect to stock solutions, the parties also agree that
the phrase "essentially free or free of ethanol" in claim 7
means "no more than 5% ethanol by volume." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id</a>.</i> Relying
on this construction, the district court found that claim 7 was
obvious, noting that the "the specification and claims of the
prior art &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2204843G0J?jcsearch=usp%204814470&amp;summary=yes#jcite">470 Patent</a>[,] . . . disclose and contemplate both
ethanol-containing and essentially ethanol-free <i>stock</i>
<i>solutions.</i> . . ." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 337</a> n. 15 (emphasis
added). Sanofi has not addressed the district court's
obviousness finding with respect to stock solutions in its
opening brief. To the extent that Sanofi's conclusory statement
in its reply that there is not "art in the record of
polysorbate stock solutions containing less than 5% ethanol,"
amounts to a challenge to the invalidity finding, that argument
is waived. <i>Advanced Magnetic Closures, Inc. v. Rome</i>
<i>Fastener Corp.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1DDN1O003?jcsearch=607%20f%203d%20817&amp;summary=yes#jcite">607 F.3d 817</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1DDN1O003?jcsearch=607%20f%203d%20817&amp;summary=yes#jcite">833</a> (Fed. Cir. 2010) ("This
court has consistently held that a party waives an argument not
raised in its opening
<span CLASS="page_no" data-cite="675 f 3d 1333" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1333" data-primary-citation="675 F.3d 1324">[*1333]</span> 
brief."). Thus, regardless of whether the court correctly
construed "essentially free or free of ethanol" as it relates
to perfusions, the district court's unchallenged finding that
the claimed stock solutions were obvious in light of the prior
art also <span CLASS="page_no" data-cite="2012 bl 84628 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> renders the "composition" in claim 7 obvious. <i>See</i>
<i>Titanium Metals Corp. v. Banner</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X4AABS?jcsearch=778%20f%202d%20775&amp;summary=yes#jcite">778 F.2d 775</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X4AABS?jcsearch=778%20f%202d%20775&amp;summary=yes#jcite">782</a>
(Fed. Cir. 1985) ("It is . . . an elementary principle of patent
law that when, as by a recitation of ranges or otherwise, a
claim covers several compositions, the claim is `anticipated'
if <i>one</i> of them is in the prior art."). We accordingly
affirm the district court's judgment that claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512
patent</a> is invalid under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                         C. Inequitable Conduct
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Sanofi also appeals the district court's determination that
both the &prime;<cite>512</cite> and &prime;<cite>561 patents</cite> are unenforceable for
inequitable conduct. As an initial matter, Sanofi contends that
the district court abused its discretion in allowing Hospira
and Apotex to amend their pleadings after the scheduling order
deadline to add allegations related to inequitable conduct
without first finding that Hospira and Apotex had established
"good cause" as required by Federal Rule of Civil Procedure
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X144L1E003?jcsearch=Fed.%20R.%20Civ.%20P.%2016(b)(4)&amp;summary=yes#jcite">16</a>(b)(4). We review a district court's granting of a motion to
amend pleadings under the law of the regional circuit.
<i>Creative Compounds, L.L.C. v. Starmark Labs.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FKI86003?jcsearch=651%20f%203d%201303&amp;summary=yes#jcite">651 F.3d 1303</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FKI86003?jcsearch=651%20f%203d%201303&amp;summary=yes#jcite">1309</a> (Fed. Cir. 2011). In the Third Circuit, such decisions
are reviewed for an abuse of discretion. <i>Race Tires Am.,</i>
<i>Inc. v. Hoosier Racing Tire Corp.</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1DMV40003?jcsearch=614%20f%203d%2057&amp;summary=yes#jcite">614 F.3d 57</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1DMV40003?jcsearch=614%20f%203d%2057&amp;summary=yes#jcite">73</a> (3d
Cir. 2010). Under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X144L1E003?jcsearch=Fed.%20R.%20Civ.%20P.%2016(b)(4)&amp;summary=yes#jcite">Rule 16(b)(4)</a>, a scheduling order "may be
modified only for good cause and with the judge's consent."
Fed.R.Civ.P. <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X144L1E003?jcsearch=Fed.%20R.%20Civ.%20P.%2016(b)(4)&amp;summary=yes#jcite">16</a>(b)(4).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_913492" href="#headnote_pq2-dec_913492">[5]</a> Here, the parties do not dispute that the scheduling order
&mdash; and consequently <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X144L1E003?jcsearch=Fed.%20R.%20Civ.%20P.%2016(b)(4)&amp;summary=yes#jcite">Rule 16(b)(4)</a>'s "good cause"
requirement &mdash; apply to Hospira's amendment. With respect
to Apotex's amendment, however, both Apotex and Hospira argue
that Apotex was never subject to the scheduling order and
therefore did not need to demonstrate good cause to amend its
pleadings. Assuming without deciding that the deadlines in the
scheduling order covered both Apotex and Hospira, we cannot say
that the district court abused its discretion in allowing the
amendments. Hospira timely asserted a claim for inequitable
conduct in its original counter-claims but, shortly after
deposing named-inventor Jean-Louis Fabre, moved to amend its
allegations after the scheduling order deadline to specifically
identify the withheld <span CLASS="page_no" data-cite="102 uspq 2d 1451" data-cite-type="ReporterOfDecisions" data-cite-pageno="1451" data-primary-citation="102 U.S.P.Q.2d 1445">[**1451]</span> <i>Vidal</i> and GV references. The
district court granted the motion, finding that "the timing of
Hospira's motion [did] not appear to have been the product of
bad faith" and that Sanofi would not be unduly prejudiced by
the amendment. Apotex then filed a motion to amend its
counterclaims to add a claim of inequitable conduct, which the
district court also granted. Given the circumstances of this
case, including the temporal proximity of the amendments to
inventor Fabre's deposition, there was good cause for the
amendments, and the district court did not abuse its discretion
in allowing them. Consequently, we turn to the merits.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that the <i>Vidal</i> and GV
references were material to patentability and that inventor
Fabre intentionally withheld them with the intent to deceive
the U.S. Patent and Trademark Office ("PTO"). Based on these
findings, the court concluded that the &prime;<cite>512</cite> and &prime;<cite>561 patents</cite>
were unenforceable for inequitable conduct. <span CLASS="page_no" data-cite="2012 bl 84628 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> Sanofi argues that
we should reverse the court's inequitable conduct judgment
because Fabre explained why he
<span CLASS="page_no" data-cite="675 f 3d 1334" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1334" data-primary-citation="675 F.3d 1324">[*1334]</span> 
did not disclose these references to the PTO and, thus, the
court's finding that he acted with the intent to deceive was
not the single most reasonable inference that could be drawn
from the evidence. Additionally, Sanofi contends that these
references were not material to patentability because they were
duplicative of references that were before the PTO. In
response, Apotex and Hospira argue that the district court's
intent findings are supported by both the evidence and the
court's credibility determinations. Regarding materiality, they
maintain that the district court properly applied the but-for
materiality analysis in concluding that the references were
material to patentability. We agree with Apotex and Hospira.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_913493" href="#headnote_pq2-dec_913493">[6]</a> In reviewing the district court's inequitable conduct
determination, we review the court's underlying factual
findings for clear error and its ultimate decision as to
inequitable conduct for an abuse of discretion. <i>Star</i>
<i>Scientific, Inc. v. R.J. Reynolds Tobacco Co.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X19RJCO003?jcsearch=537%20f%203d%201357&amp;summary=yes#jcite">537 F.3d 1357</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X19RJCO003?jcsearch=537%20f%203d%201357&amp;summary=yes#jcite">1365</a> (Fed. Cir. 2008). To prevail on an inequitable conduct
defense, a defendant must establish both the materiality of the
withheld reference and the applicant's intent to deceive the
PTO. <i>Therasense, Inc. v. Becton, Dickinson &amp; Co.</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">649 F.3d 1276</a>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">1290</a> (Fed. Cir. 2011) (en banc). In
<i>Therasense</i>, this court rejected the "sliding scale"
approach to proving inequitable conduct "where a weak showing
of intent may be found sufficient based on a strong showing of
materiality, and vice versa." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id</a>.</i> Instead, we
instructed that "[i]ntent and materiality are separate
requirements." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id</a>.</i> Additionally, we held that but-for
materiality is the standard for evaluating the materiality
prong of the analysis unless there is affirmative egregious
misconduct. <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id. at 1292</a>. In this case, although the
district court did not have the benefit of our
<i>Therasense</i> opinion when it rendered its inequitable
conduct decision, the court nevertheless found that the
withheld references were but-for material to patentability and
made distinct intent and materiality findings rather than
employing the now-abrogated sliding scale approach.
Consequently, as set forth below, we conclude that the court's
inequitable conduct determination withstands even the more
rigorous standard adopted in <i>Therasense.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                             1. Materiality
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  prior art reference "is but-for material if the PTO would not
have allowed a claim had it been aware of the undisclosed prior
art." <i>Therasense</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">649 F.3d at 1291</a>. Unlike the clear
and convincing evidence standard for invalidating a patent in
the district court under <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVC003?jcsearch=35%20usc%20102&amp;summary=yes#jcite">35 U.S.C. &sect;&sect; 102</a> and <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">103</a>, the
standard for establishing but-for materiality in the
inequitable conduct context only requires a preponderance of
the evidence, "giv[ing] claims their broadest reasonable
construction." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id. at 1291-92</a>. As a result, when a
"claim is properly invalidated in district court based on the
deliberately withheld reference, then that reference is
necessarily material" for purposes of the inequitable conduct
inquiry. <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id. at 1292</a>. <span CLASS="page_no" data-cite="2012 bl 84628 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> On the other hand, even if the
withheld reference is not sufficient to invalidate the claim in
district court, "the reference may be material if it would have
blocked patent issuance under the PTO's different evidentiary
standards." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, we have affirmed the district court's finding that the
&prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a> were invalid based <i>on</i>, inter
alia, the withheld GV and <i>Vidal</i> references. Because
such references are necessarily material to patentability, the
district court did not err in finding that the materiality
requirement was established.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                2. Intent
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To satisfy the intent requirement, "the accused infringer must
prove
<span CLASS="page_no" data-cite="675 f 3d 1335" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1335" data-primary-citation="675 F.3d 1324">[*1335]</span> 
by clear and convincing evidence that the applicant knew of
the reference, knew that it was material, and made a deliberate
decision to withhold it." <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id</a>.<span CLASS="page_no" data-cite="102 uspq 2d 1452" data-cite-type="ReporterOfDecisions" data-cite-pageno="1452" data-primary-citation="102 U.S.P.Q.2d 1445">[**1452]</span> </i> In <i>Therasense</i>,
we confirmed that inequitable conduct requires clear and
convincing evidence of a specific intent to deceive the PTO and
that "the specific intent to deceive must be `the single most
reasonable inference able to be drawn from the evidence.'"
<i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id</a>.</i> (quoting <i>Star Scientific</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X19RJCO003?jcsearch=537%20f%203d%201357&amp;summary=yes#jcite">537 F.3d at 1366</a>). "This court reviews the district court's factual
findings regarding what reasonable inferences may be drawn from
the evidence for clear error." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1FGJ4I003?jcsearch=649%20F.3d%201276&amp;summary=yes#jcite">Id. at 1291</a>. In this
case, the district court heard extensive testimony from
inventor Fabre regarding both the <i>Vidal</i> and GV
references, and the court's finding that Fabre acted with a
specific intent to deceive the PTO in withholding those
references is not clearly erroneous.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The <i>Vidal</i> reference discloses Sandoz's experience
using polysorbate 80 as a surfactant with the cancer drug
etoposide. During the trial, Fabre testified that he did not
cite the <i>Vidal</i> reference to the PTO because the
etoposide-type experiments he and his co-inventors performed
with doxcetaxel resulted in perfusions that did not demonstrate
eight hours of stability. According to Fabre, he believed that
these experiments were failures and that he therefore did not
need to disclose the <i>Vidal</i> reference to the PTO.
Sanofi argues that based on this testimony the district court
erred in finding that Fabre had the specific intent to deceive
the PTO because that finding was not the single most reasonable
inference that could be drawn. We disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court considered Fabre's explanation for
withholding the <i>Vidal</i> reference and expressly rejected
it based on both the evidence presented and the finding that
Fabre lacked credibility. Specifically, the district court
relied on Fabre's testimony that he learned of replacing
Cremophor with polysorbate 80 from the <i>Vidal</i> reference
and that the Sandoz experience disclosed in the reference was
one of the "main factors that shaped [his] thinking" in
choosing polysorbate 80 and led him to believe that replacing
Cremophor with polysorbate 80 would avoid anaphylactic
manifestations. <i>Aventis</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">743 F.Supp.2d at 351-53</a>. This
testimony also was consistent with a Sanofi internal memorandum
acknowledging the side effects associated with Cremophor and
noting that Sandoz had used polysorbate 80 (i.e., "TWEEN")
instead <span CLASS="page_no" data-cite="2012 bl 84628 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> of Cremophor in its etoposide product. <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id.
at 351</a>; J.A. 5666.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In making its intent finding, the district court also
emphasized that in Fabre and his co-inventors' submissions to
the PTO, they cited the Rowinsky reference, which identified
the "problem" the inventors were trying to solve &mdash; i.e.,
the anaphylactic reactions associated with Cremophor &mdash;
but did not cite the <i>Vidal</i> reference, which revealed
the "solution" &mdash; i.e., the switch from Cremophor to
polysorbate 80. <i>Aventis</i>, <a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">743 F.Supp.2d at 352</a>. The
court found that "[t]here simply is no justification for
telling the [PTO] about the prior art disclosing the problem
[Fabre] examined while concealing key prior art disclosing the
solution he chose." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 353</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, in addressing Fabre's excuse that he withheld the
<i>Vidal</i> reference because the etoposide-type experiments
he and his co-inventors performed were failures, the court
found that Fabre's testimony was not credible. The court
determined that during Fabre's direct examination he did not
address all of the etoposide-type experiments that he and his
colleagues had undertaken but rather only reviewed those
experiments that demonstrated low stability and thus supported
Fabre's excuse for not disclosing the reference. The remaining
experiments
<span CLASS="page_no" data-cite="675 f 3d 1336" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1336" data-primary-citation="675 F.3d 1324">[*1336]</span> 
discussed during Fabre's cross-examination, however,
displayed stabilities ranging from five hours and forty minutes
to over thirty hours. <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 352-53</a>; J.A. 5566-69.
Fabre attempted to downplay the significance of these
experiments by stating that they were not "etoposide-type
formulations." But the district court found that Fabre's
testimony was contrary to the titles of the Sanofi documents
detailing those experiments and lacked credibility: "The court
does not find credible Fabre's witness-stand assertion, twenty
years after the documents were prepared, that the
contemporaneous description of these formulations as
`etoposide-type' did not reflect how Sanofi's researchers
actually viewed the formulations." <i>Aventis</i>,
<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">743 F.Supp.2d at 353</a>. Based on the evidence and his assessment of
Fabre's testimony, the court found that Fabre "knew that the
<i>Vidal</i> reference and the other etoposide prior art were
relevant to the patentability of his alleged invention, but
nonetheless chose not to disclose it to the patent office."
<i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id</a>.</i> From this finding, the court concluded that Fabre
acted with the intent to deceive the PTO when he withheld the
<i>Vidal</i> reference. <i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In light of the evidence before the district court supporting
the finding of a specific intent to deceive, coupled with the
deference we must afford to the district court's credibility
determinations, we cannot conclude that the court's finding
that Fabre withheld the <i>Vidal</i> reference with the
specific intent to deceive the PTO was clearly erroneous.
<span CLASS="page_no" data-cite="102 uspq 2d 1453" data-cite-type="ReporterOfDecisions" data-cite-pageno="1453" data-primary-citation="102 U.S.P.Q.2d 1445">[**1453]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We reach the same conclusion with respect to the GV reference.
The GV reference describes the relationship between the
structure and activity of various analogues of paclitaxel
including docetaxel and names one of Fabre's colleagues as an
author. Specifically relevant to the patentability of the
patents at issue, <span CLASS="page_no" data-cite="2012 bl 84628 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> the reference states: "Moreover Taxotere
(13a) showed a better solubility in excipient system
(polysorbate 80/ethanol, 1:1). . . ." J.A. 5631. Fabre
testified that he did not cite the GV reference to the PTO
because he only read a March 1990 draft of the reference which
did not include this sentence disclosing the polysorbate
80/docetaxel formulation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Again, the district court found that this testimony was not
credible and relied on the other evidence presented during the
trial in finding that Fabre withheld the reference with the
specific intent to deceive the PTO. The court explained that
Fabre was the project leader of Sanofi's Taxotere development,
had to approve the GV reference for publication, and had
testified that he reviewed the article "with some care to make
sure that it was a proper article for the company to be
publishing." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 353-54</a>. The court further
highlighted Fabre's testimony that in March 1992, he was
dissatisfied with the clinical brochure for Taxotere because it
did not list the GV reference and affirmatively took steps to
ensure that the reference was identified. Six months later,
however, when Fabre signed his patent declaration, he failed to
disclose the reference to the PTO. <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 353</a>. Relying
on this evidence, the district court found that Fabre
"`reviewed . . . with some care' the final version of the GV
reference prior to signing the patent declaration, was aware of
the reference's materiality to the prosecution of his patents,
and purposefully decided not to disclose it despite this
knowledge." <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 354</a>. Thus, contrary to Sanofi's
contention, in concluding that Fabre acted with a specific
intent to deceive the PTO, the district court did not rely
solely on its finding that Fabre was not credible but instead
viewed Fabre's testimony in light of the other evidence to
reach its intent conclusion. Based on the
<span CLASS="page_no" data-cite="675 f 3d 1337" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1337" data-primary-citation="675 F.3d 1324">[*1337]</span> 
evidence presented, this finding was not clearly erroneous.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Relying on these materiality and intent findings, the district
court found the patents were unenforceable due to inequitable
conduct. <i></i><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1E9D3G003?jcsearch=743%20F.%20Supp.%202d%20305&amp;summary=yes#jcite">Id. at 354</a>. Based on the district court's
thorough discussion of its factual findings and its
well-reasoned analysis that is consistent with
<i>Therasense</i>, this determination was not an abuse of
discretion. We accordingly affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                             III. CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We have considered Sanofi's additional arguments for reversing
the district court's decision and conclude that they similarly
lack merit. Consequently, for the reasons set forth above, the
district court's judgment that claim 5 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561 patent</a> and
claim 7 of the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patent</a> are invalid for obviousness and that
the &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HOK05308J?jcsearch=usp%205750561&amp;summary=yes#jcite">561</a> and &prime;<a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X2HO4850GGJ?jcsearch=usp%205714512&amp;summary=yes#jcite">512 patents</a> are unenforceable for inequitable
conduct is affirmed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<!--BBLS DD 1699327115267-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HEJSK003/history">Direct History (4)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HEJSK003/analysis">Case Analysis (38)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HEJSK003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
34
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HEJSK003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
4
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/55858d43ba3198188cf428e920907029/document/X1Q6LF212682">11-01018 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Evidence</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/55858d43ba3198188cf428e920907029/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "55858d43ba3198188cf428e920907029";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYfae707&previousPageId=&previousActivityInstanceId=ENTITYf60d69&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:43:04-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HEJSK003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYf60d69&previousPageId=&previousActivityInstanceId=ENTITY3ac93e&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:42:58-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HEJSK003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HEJSK003";
$('#page_loader').show().spin();
JUDGE_IDS=["3408847","3496219","4063892"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
